Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines Inc (NQ: PRAX )

51.14 -1.26 (-2.40%)
Streaming Delayed Price Updated: 9:45 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines Inc

< Previous 1 2 3 4 5 Next >
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Recap: Praxis Precision Medicine Q4 Earnings
Via Benzinga
Praxis Precision Medicines to Participate in Upcoming April Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81... 
Via Benzinga
Why Praxis Precision Medicines Stock Is Trading Higher Tuesday
Praxis Precision Medicines updates Phase 2a study on PRAX-628 in epilepsy patients with photo paroxysmal response, indicating positive response and safety profile, advancing plans for focal epilepsy... 
Via Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big
The company said 100% of patients who received the high dose responded to its drug. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Host PRAX-628 Program Update
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Beats Revenue for Q4 2023
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky." 
Via Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.